GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Plenty of buying today Northeast, but hopefully no news just yet as I'm planning to buy a few myself tomorrow, with funds incoming. Gl :-)
Welcome Score!
I have it at roughly 2.5m if buys today. Most showing as sells. Somethings happening maybe another TR1 will show soon.
1500 could turn into a lot of money in 2 years will take a stake to start
Yes indeed Northeast, no doubt Madrigal will want to protect/dominate the Nash space by acquisition , as well as other Major's currently involved in Nash R & D...... Exciting times ahead. Gl ;-)
Money,
My thoughts on this when I read they may look at acquisitions. Genflow will 100% get looked at here. Especially after that paper being released last week re patent! They have everything that big pharma’s need. We have the R&D and the patents to back it. Fantastic!
Other biopharma players including Pfizer, Bristol Myers Squibb and Genfit have all tried to get into the NASH field as well. Madrigal’s offering, meanwhile, was the first to meet the goals of both MASH resolution and fibrosis improvement in a phase 3 study.
The company is pricing Rezdiffra at a wholesale acquisition cost of $47,400 before discounts. Analysts at Evercore ISI have previously pegged peak global sales at $5.5 billion, and the analyst team expects the drug to generate about $2.6 billion in 2030.
Crucially, the FDA’s approval comes without the requirement of a liver biopsy to determine patient eligibility. That was a major point of contention among investors ahead of the approval, as the invasive procedure would have constrained wide access to the med.
hTtps://www.fiercepharma.com/pharma/after-monumental-mash-nod-its-rezdiffra-madrigal-plots-600m-stock-sale-support-upcoming
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,546 followers
3d
Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is glad to see the mounting interest in Nonalcoholic Steatohepatitis (NASH). The field was notably understudied until recently, when Genflow Biosciences and fellow pioneers began developing promising new treatments revolving around #SIRT6.
Our CEO, Dr Eric Leire, points to a recent EMBO Press report as an example of the growing attention, which also lends support to our research in #NASH.
Read the report here: hTtps://loom.ly/Z_O_-tE
FDA approves Madrigal’s Rezdiffra as first drug for fatty liver disease NASH
Over six million people in the US are affected by NASH with moderate-to-advanced liver scarring
19th March 2024
The US Food and Drug Administration (FDA) has approved Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis, alongside diet and exercise.
Based on results from the MAESTRO-NASH trial, the accelerated approval marks Rezdiffra as the first treatment option available to address notable liver scarring and liver damage.
htTps://pmlive.com/pharma_news/fda-approves-madrigals-rezdiffra-as-first-drug-for-fatty-liver-disease-nash/
HTtps://uk.marketscreener.com/insider/JONATHAN-SWANN-A256MW/
TR1 - Major Holdings Notification
Name
Jonathan Mark Swann
City of registered office (if applicable)
rickmansworth
Country of registered office (if applicable)
United Kingdom
RNS Number : 6661H
Genflow Biosciences PLC
21 March 2024
21 March 2024
Genflow Biosciences Plc
Announces Publication of a Key European Patent in Partnership with University of Rochester, New York, et al.
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce a significant milestone in its journey. Genflow's collaborative partners, including the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, have received confirmation that their European patent application was published today by the European Patent Office, bearing the reference number EP 4 338 267.
Innovation in Age-Related Disease Prevention and Treatment
The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," enhances the understanding and potential treatment of diseases associated with aging by focusing on the SIRT6 gene/protein, known for its critical role in DNA repair, metabolism, and longevity.
SIRT6 regulates DNA damage repair, specifically double strand breaks (DSB) and prevents or delays aging of cells. Genflow's lead drug candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene. Genflow is currently undertaking key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of GF-1002 and its potential benefits, initially, for non-alcoholic steatohepatitis (NASH) patients.
In 2023, the Company received positive feedback from the Federal Agency for Medicines and Health Products in Belgium and expects a follow-up meeting in Q2 2024 to finalise design of Phase/II clinical trials. NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD) characterized by excessive fat deposits in the liver, is usually a silent disease with few, if any, symptoms, and effective treatments.
Dr. Eric Leire, CEO of Genflow commented: "This approval from the European Patent Office highlights the innovative spirit of our collaborative team and we are incredibly proud to be part of this pioneering research alongside such respected institutions." He continued, "This patent represents a leap forward in our understanding and capabilities in treating age-related conditions and marks a significant step forward in our mission to develop effective therapies for NASH and other age-related diseases."
Orders being fulfilled though. Nice discount for those who scoop :P
Drop is garbage
Spread is Garbage
Share price is garbage
Have i missed anything?
Yep, he also hinted at institutional investors which would make all the difference to current sp performance. Gl ;-)
I really enjoyed watching Eric’s presentation. Good to know the company is going for FDA approvals by the end of April. We all know the US is where the money and big pharma are for mergers and acquisitions!
Eric's presentation. Gla ;-)
Genflow Biosciences Plc (OTCQB: GENFF | LSE: GENF): Virtual Investor Conferences
hTtps://www.youtube.com/watch?v=0ZhaxbymGk4
100%, still waiting on confirmation of receipt of funds, news from trials so far to date, further JV’s and research partners, further funding, news on patent applications, possibility of further patents, future development plans on new and existing programmes, possible takeover companies sniffing around. Anything could happen 😁
Yes indeed Porter, I was thinking we could get news before the presentation anytime from Monday morning, maybe that's why Eric has the first slot!!!??? Gl:-)
I’d completely forgot about that munch. That would certainly be amazing if there was a big announcement on the presentation.
Ps Northeast, and how great would it be if Eric's presentation was backed up by some stellar news from Vera and Co from the crucial invivo studies which were expected end of 2023.....looking forward to this coming week.....Gl ;-)
Nice one Northeast, and Genflow are first to present. Gl ;-)
hTtps://www.virtualinvestorconferences.com/events/event-details/life-science-investor-forum-2
Virtual investor conference 7th March. Featuring GENFLOW and other US trading company’s in Life Science! Couple of the Big Nasdaq companies also presenting. Some great exposure
Nice to see Genflow listed among the top longevity and pharma companies:
https://www.medicalstartups.org/top/aging/
100%. If the dogs can 10 bag, imagine what Genflow can do with a splash of positive news, given the fact that the mergers and acquisitions market is in fire!
1.45?....today,could be the end of the downtrend..imo
let's see
gla